Brief: Crescita Therapeutics Q4 revenue CAD 4.725 million
13/03/2024 11:39
Mar 13 (Reuters) - Crescita Therapeutics Q4 gross margin 64.8%. * Q4 revenue CAD 4.725 million * Q4 adjusted EBITDA CAD 245 thousand * Q4 pretax profit CAD 47 thousand * Q4 operating expenses CAD 3.173 million * Q4 operating income CAD -113 thousand
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium